Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | Director | August 25, 2017 | August 29, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date August 25, 2017 · Filed August 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,000 |
Reported balance
After 2017-08-25 transaction · row 1
1 source rowRow 1 · 2017-08-25 · Purchase · Acquired 2,000 · Balance 7,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2017 Filed Aug 29, 2017 00:46 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 2,000 | $3.31 | $6,620.00 |
DisclosureSEC source: 0001415889-17-001429 · form4-08282017_050826.xml · nonDerivative · entry 1 Allen Stephen R. · CIK 0001597090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| June 20, 2017 Filed Jul 3, 2017 21:14 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-17-001083 · form4-07032017_020713.xml · derivative · entry 1 Allen Stephen R. · CIK 0001597090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · derivative.exercise_date: Options vest 100% on June 20, 2018. Read SEC document |
| May 19, 2017 Filed May 22, 2017 23:52 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 3,000 | $3.20 | $9,600.00 |
DisclosureSEC source: 0001415889-17-000816 · form4-05222017_040552.xml · nonDerivative · entry 1 Allen Stephen R. · CIK 0001597090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 20:33 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 2,000 | $2.81 | $5,620.00 |
DisclosureSEC source: 0001415889-17-000459 · form4-03212017_010305.xml · nonDerivative · entry 1 Allen Stephen R. · CIK 0001597090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:33 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001415889-16-007474 · form4-11182016_011150.xml · derivative · entry 1 Allen Stephen R. · CIK 0001597090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-11-16 F1 · derivative.exercise_date: Options vest 100% on November 16, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.